Management ChangeMay 21, 2026, 08:02 AM
Corbus Pharma Appoints Nishant Saxena as First Chief Business Officer
AI Summary
Corbus Pharmaceuticals Holdings, Inc. announced the appointment of Nishant Saxena as its first Chief Business Officer, signaling a strategic move towards commercialization and value creation. The company also revealed plans to host a conference call and webcast on May 26 to discuss updated Phase 1/2 data for CRB-701 in head and neck squamous cell carcinoma (HNSCC) and cervical cancer, which will be presented at the 2026 ASCO Annual Meeting. Additionally, Corbus anticipates two key pipeline milestones this summer: the initiation of a registrational study for CRB-701 in second-line HNSCC and the completion of the CANYON-1 Phase 1b study for CRB-913 in obesity.
Key Highlights
- Corbus Pharma appointed Nishant Saxena as its first Chief Business Officer.
- Company to host a conference call on May 26 at 8:00 a.m. EDT for CRB-701 data.
- Updated Phase 1/2 data for CRB-701 in HNSCC and cervical cancer to be presented at 2026 ASCO.
- Data cut-off for CRB-701 presentation is April 1, 2026, including durability and HNSCC subgroup analysis.
- Anticipates initiating a registrational study for CRB-701 in second-line HNSCC this summer.
- Anticipates completing the CANYON-1 Phase 1b study (n=240) for CRB-913 this summer.
- Nishant Saxena brings over 20 years of experience, including as a former Evercore Managing Director.
- Corbus will host an in-person and virtual KOL event on June 1, 2026, during ASCO for CRB-701 HNSCC data.
Price Impact
More from CRBP